Latanoprost emulsion - Santen SAS

Drug Profile

Latanoprost emulsion - Santen SAS

Alternative Names: Catioprost; Nova21027

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Novagali Pharma
  • Developer Santen S.A.S.
  • Class Antiglaucomas; Prostaglandins; Small molecules
  • Mechanism of Action Prostaglandin F2 alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Glaucoma; Ocular hypertension

Most Recent Events

  • 27 Aug 2015 Phase-II development for Glaucoma and Ocular hypertension is ongoing in Europe
  • 27 Aug 2015 No recent reports on development identified - Phase-II for Glaucoma and Ocular hypertension in USA (Topical)
  • 08 May 2013 Novagali Pharma SAS is now called Santen SAS
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top